Annovis Bio (ANVS) announced the issuance of U.S. Patent No. 12,582,632 B2, covering prevention and treatment of neurological injuries arising from brain infections through the administration of buntanetap or related compounds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio enters partnership with NeuroRPM
- Annovis Bio sees cash runway to 3Q26
- Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year
- Annovis Bio: Advancing Phase 3 Neurodegeneration Programs Create Attractive Risk‑Reward Supporting Buy Rating
- Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod